BEAM - Beam Therapeutics Inc.

QQQ $ 481.15 $ 6.24 (1.31 %)

DIA $ 409.09 $ 2.37 (0.58 %)

SPY $ 559.11 $ 5.30 (0.96 %)

TLT $ 97.90 $ 0.45 (0.46 %)

GLD $ 231.62 $ -0.38 (-0.16 %)

Previous Close

$ 25

Open

$ 24.40

Bid

$ 24.96 x 100

Ask

-- x --

Day's Range

$ 24.40 - $ 25.62

52 Week Range

$ 16.95 - $ 49.50

Volume

1,030,962

Average Volume

Market Cap

2.06B

Beta (5Y Monthly)

$ 1.26

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-08-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-10-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-07-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-08-2021	09-30-2021	10-Q
13	08-10-2021	06-30-2021	10-Q
14	05-11-2021	03-31-2021	10-Q
15	03-15-2021	12-31-2020	10-K
16	11-10-2020	09-30-2020	10-Q
17	08-12-2020	06-30-2020	10-Q
18	05-12-2020	03-31-2020	10-Q
19	03-30-2020	12-31-2019	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

gene-editing-korro-bios-preclinical-data-best-in-class-analyst-initiates-with-outperform-rating

Gene Editing Korro Bio's Preclinical Data ...
08/14/2024 18:21:10

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst r...

JP Morgan Maintains Overweight on Beam The...
08/07/2024 17:14:16

JP Morgan analyst Eric Joseph maintains Beam Therapeutics (NASDAQ:BEAM) with a Overweight and raises the price target from $...

Barclays Maintains Equal-Weight on Beam Th...
08/07/2024 16:38:33

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $3...

RBC Capital Reiterates Sector Perform on B...
08/07/2024 15:36:32

RBC Capital analyst Luca Issi reiterates Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and maintains $27 price target.

Beam Therapeutics Says Ended Q2 2024 With ...
08/06/2024 10:40:29

Beam Therapeutics Q2 2024 GAAP EPS $(1.11)...
08/06/2024 10:39:41

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1...

viasat--ast-spacemobile-are-among-top-6-mid-cap-stocks-that-shined-the-brightest-last-week-july-21-july-27-are-the-others-in-your-portfolio

ViaSat & AST SpaceMobile Are Among Top 6 M...
07/28/2024 18:17:42

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

ibm-posts-upbeat-earnings-joins-servicenow-helmerich--payne-rtx-nasdaq-and-other-big-stocks-moving-higher-on-thursday

IBM Posts Upbeat Earnings, Joins ServiceNo...
07/25/2024 16:59:19

danaher-posts-upbeat-earnings-joins-spotify-msci-owens--minor-and-other-big-stocks-moving-higher-on-tuesday

Danaher Posts Upbeat Earnings, Joins Spoti...
07/23/2024 15:04:22

HC Wainwright & Co. Initiates Coverage On ...
07/23/2024 11:14:08

HC Wainwright & Co. analyst Patrick Trucchio initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and...

cathie-wood-led-ark-invest-sells-8m-in-tesla-shares-despite-bullish-autonomy-forecast

Cathie Wood-Led Ark Invest Sells $8M In Te...
07/19/2024 02:12:11

Beam Therapeutics Has Initiated A Search F...
07/15/2024 10:33:43

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

Beam Therapeutics Announced The First Pati...
06/26/2024 10:34:29

Beam Therapeutics Highlights Improved Manu...
06/14/2024 08:24:59

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, tod...

Beam Therapeutics Presents Data Highlighti...
05/14/2024 20:00:52

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

Barclays Maintains Equal-Weight on Beam Th...
05/08/2024 18:03:40

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $4...

Beam Therapeutics Ended Q1 2024 With $1.1B...
05/07/2024 10:39:46

Beam Therapeutics Q1 2024 GAAP EPS $(1.21)...
05/07/2024 10:38:59

Expert Ratings For Beam Therapeutics
04/23/2024 18:00:16

Wedbush Reiterates Outperform on Beam Ther...
04/23/2024 16:32:11

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $57 price target.